CinCor is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases. Baxdrostat is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. Baxdrostat has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure.
We are evaluating the efficacy and safety profile of baxdrostat as a potential treatment for the broader hypertensive population, including different subpopulations of hypertensive patients who have not achieved blood pressure control despite treatment. We have completed a Phase 2 clinical trial, which we refer to as our BrigHtn trial, of baxdrostat in patients whose blood pressure is not controlled despite treatment with three or more antihypertensive agents, including a diuretic, which is referred to as treatment resistant hypertension, or rHTN. We reported positive topline BrigHtn results in August 2022. We have an ongoing Phase 2 clinical trial, which we refer to as our HALO trial, in patients with whose blood pressure is not controlled despite treatment with one or more antihypertensive agent, which is referred to as uncontrolled hypertension, or uHTN. An open-label extension clinical trial for patients previously enrolled in our HALO trial has been initiated to evaluate the long-term safety and effectiveness of baxdrostat, which we refer to as our OLE trial.
In addition to hypertension, we are developing baxdrostat for the treatment of primary aldosteronism, or PA, and we are exploring its utility in ameliorating complications of chronic kidney disease, or CKD. In 2021, we initiated a Phase 2 clinical trial of baxdrostat in patients with PA, which we refer to as our spark-PA trial. In 2022, we initiated a Phase 2 clinical trial in patients with CKD who have uncontrolled blood pressure, which is referred to as our figHtn-CKD trial.
The people behind CinCor Pharma are not only experienced, they’re phenomenal.
Marc de Garidel
Marc de Garidel has served as our Chief Executive Officer and a member of our board of directors since July 2021. Mr. de Garidel serves on the board of directors of Claris Biotherapeutics, Inc. Prior to September 2020, Mr. de Garidel served as the Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2018 until their acquisition by Novo Nordisk A/S in August 2020. Mr. de Garidel also served as the Chief Executive Officer of Ipsen SA from November 2010 to July 2016, and has served as the chairman of Ipsen’s board of directors since November 2010. Mr. de Garidel started his career at Eli Lilly & Co and then served 15 years in multiple growing responsibility roles at Amgen in the US and Europe.
EVP, CFOMichael Kalb joined CinCor in November 2022 as our Executive Vice President and Chief Financial Officer. Previously, he was the Chief Financial Officer of Amarin Corporation plc from June 2016 through June 2022. Prior to joining Amarin, Mr. Kalb served as Chief Financial Officer and Chief Accounting Officer of Taro Pharmaceutical Industries, Ltd. Prior to Taro, Mr. Kalb was a director in Huron Consulting Group Inc.’s Financial Consulting Group. Mr. Kalb’s experience also includes over ten years at Ernst & Young, LLP within its Transaction Advisory Services Group and Audit and Assurance Services Group. He is a certified public accountant.
Catherine Pearce, DHSc
COO & co-founder
Catherine Pearce, M.B.A., D.HSc., co-founded our company in 2018 and has served as our Chief Operating Officer since May 2019. Previously, Ms. Pearce served as both the Chief Operating Officer of CinRx and the vice president, strategic alliances at Medpace from September 2015 until August 2021. Ms. Pearce also served as the Vice President, Research and Development at Teva Pharmaceutical Industries Ltd. from April 2013 until September 2015.
Mason W. Freeman, MD
Since joining CinCor in August 2021, Mason Freeman, M.D., initially served as our Executive Vice President, Clinical Development and, as of March 2022, serves as our Chief Medical Officer. He has also served as a member of our scientific advisory board since June 2019. Additionally, Dr. Freeman serves as a Venture Partner at 5AM Venture Management, LLC, a position he has held since May 2008, as well as the Director of the Massachusetts General Hospital’s Translational Research Center. Previously, Dr. Freeman served as a member of the board of directors of scPharmaceuticals Inc. from July 2018 to December 2020 and Crinetics Pharmaceuticals, Inc. from November 2015 to July 2019.
SVP & Head of People, Talent and CultureIda Hatoum has served as our Senior Vice President, Head of People, Talent and Culture since May 2022. Most recently Ms. Hatoum was the Head of Organizational Development and Training at BioDelivery Sciences from 2014 until joining CinCor. She spent the first 10 years of her career with Roche Diagnostics and Astra Zeneca in the cardiovascular space. She quickly escalated into numerous leadership roles and has over 14 years’ experience leading talent development and culture for several organizations as they scaled from early clinical stage to commercialization.
Senior Management Team
Nadege Briancon-Eris, Ph.D.
Senior Director, Program Management
Senior Director, Quality Assurance
Vice President, CMC and Quality Control
Yuan-Di Halvorsen, Ph.D.
Vice President, Clinical Operations
James Hui, Ph.D.
Vice President, Clinical Pharmacology and Translational Research
Senior Director, Clinical Data Management
William (Bill) Marshall, MD
Vice President, Medical
Kevin Schutz, PharmD
Vice President, Regulatory Affairs
Justin Thompson, MS
Vice President, Business Development
James Healy, MD, Ph.D.
David Allison, Ph.D.
Maina Bhaman, MBA
Marc de Garidel
Chief Executive Officer
Jason Pitts, Ph.D.
John F. Thero
June Lee, MD
Scientific Advisory Board
Morris Brown, MD
Professor of Endocrine Hypertension, Queen Mary, UK
Ulrich Granzer, PhD
Granzer Regulatory and Consulting Services
John Kastelein, MD
Emeritus Professor of Medicine at the Academic Medical Center (AMC) of the University of Amsterdam
Suzanne Oparil, MD
Professor of Medicine / Hypertension Program at University of Alabama
Patrick Rossignol, MD
Professor of Therapeutics, Nephrologist and Vascular Medicine Specialist, Université de Lorraine (France)
Philip T. Sager, MD
Former Chair - FDA Cardiovascular and Renal Advisory Committee
Bryan Williams, MD
Chair of Medicine at UCL, National Institute for Health Research Senior Investigator Emeritus (UK)